Drug Trial Radar · NCT03452228
Safety and Efficacy Following Repeat-Dose of Evinacumab (Anti-ANGPTL3) in Patients With Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis
Last checked: Nov 20, 2026Latest source record: Feb 16, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
52
Actual
Start
Jun 7, 2018
Primary completion
Dec 17, 2019
Study completion Jul 23, 2020
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Mar 2, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective is to determine the change in Triglyceride (TG) levels following 12 weeks of repeated Intravenous (IV) doses of evinacumab.
Conditions
- Severe Hypertriglyceridemia (sHTG)
Interventions
evinacumabDrug
Administered by Intravenous (IV)
PlaceboDrug
Administered by Intravenous (IV)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change From Baseline in Fasting Triglycerides (TG) Level Following 12 Weeks of Repeated IV Doses of Evinacumab in Actual Cohort 3 ParticipantsTime frame: Participants randomized to evinacumab: Week 0 corresponds to Baseline and 12 weeks treatment corresponds to Week 12 of the DBTP; Participants randomized to placebo: Week 12 corresponds to Baseline and 12 weeks treatment corresponds to Week 24 of the SBTP
Locations
17 sites in 4 countries. Site status is shown where the registry gives one.
Regeneron Research Facility
Boca Raton, Florida
Regeneron Research Facility
Atlanta, Georgia
Regeneron Research Facility
Kansas City, Kansas
Regeneron Research Facility
New York, New York
Regeneron Research Facility
Philadelphia, Pennsylvania
Regeneron Research Facility
Pittsburgh, Pennsylvania
Regeneron Research Facility
Dallas, Texas
Regeneron Research Facility
Houston, Texas
Regeneron Research Facility
Milwaukee, Wisconsin
Regeneron Research Facility
Chicoutimi, Quebec, Canada
Regeneron Research Facility
Québec, Quebec, Canada
Regeneron Research Facility
Rome, Italy
Regeneron Research Facility
Naples, Campania, Italy
Regeneron Research Facility
Birmingham, United Kingdom
Regeneron Research Facility
London, United Kingdom
Regeneron Research Facility
London, United Kingdom
Regeneron Research Facility
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.